Key Insights

Highlights

Treatment Research

3 treatments under study, led by Data Collection And Quality Of Life Questionnaire

Research Leaders

10 sponsors active, led by AstraZeneca

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04151342Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

NCT04921553Unknown

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Showing all 2 trials

Research Network

Common Treatments

  • Data Collection And Quality Of Life Questionnaire1
  • Patientreported Outcomes Pros1
  • Cancer Treatment With Tyrosine Kinase Inhibitors Tkis Or Other Molecularly Targeted Therapeutic Agents1

Active Sponsors

  • AstraZeneca1
  • Nuvation Bio Inc.1
  • Centre Leon Berard1
  • IQVIA Solutions Canada Inc.1
  • Bayer1

Top Investigators

Related Conditions

  • Cancer2
  • Cancer Metastatic1
  • Molecular Sequence Variation1
  • Ntrk Family Gene Mutation1
  • Ros1 Gene Translocation1

Activity Timeline